Vivesto (VIVE) Stock Overview
Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VIVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Vivesto AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.23 |
| 52 Week High | SEK 0.37 |
| 52 Week Low | SEK 0.20 |
| Beta | 1.08 |
| 1 Month Change | 0.87% |
| 3 Month Change | 2.21% |
| 1 Year Change | -13.94% |
| 3 Year Change | -66.79% |
| 5 Year Change | -95.55% |
| Change since IPO | -99.11% |
Recent News & Updates
Shareholder Returns
| VIVE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -0.2% | -1.5% | -0.7% |
| 1Y | -13.9% | -11.4% | -3.0% |
Return vs Industry: VIVE underperformed the Swedish Biotechs industry which returned -11.4% over the past year.
Return vs Market: VIVE underperformed the Swedish Market which returned -3% over the past year.
Price Volatility
| VIVE volatility | |
|---|---|
| VIVE Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: VIVE has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: VIVE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 4 | Erik Kinnman | www.vivesto.com |
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
Vivesto AB Fundamentals Summary
| VIVE fundamental statistics | |
|---|---|
| Market cap | SEK 124.56m |
| Earnings (TTM) | -SEK 39.62m |
| Revenue (TTM) | n/a |
Is VIVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIVE income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 39.62m |
| Earnings | -SEK 39.62m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 12, 2025
| Earnings per share (EPS) | -0.074 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VIVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/20 15:53 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vivesto AB is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Klas Palin | DNB Carnegie Commissioned Research |
| Susie Jana | Edison Investment Research |